About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker ALDX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 10, 2026A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)
NCT05717920 · Atopic Dermatitis
ADX-629 (Open-label)
ALDX
Aldeyra Therapeutics, Inc.
Phase 2Completed8Nov 21, 2023Registry ↗
Jun 3, 2026A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatiti…
NCT06685692 · Alcohol Hepatitis
ADX-629, ADX-629
ALDX
Aldeyra Therapeutics, Inc.
Phase 2Completed4Jun 18, 2025Registry ↗
May 14, 2026The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasona…
NCT05234554 · Allergic Conjunctivitis
Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic…
ALDX
Aldeyra Therapeutics, Inc.
Phase 3Completed131Apr 22, 2023Registry ↗
Apr 23, 2026A Study in Subjects With Retinitis Pigmentosa
NCT05392179 · Retinitis Pigmentosa
ADX-2191, ADX-2191
ALDX
Aldeyra Therapeutics, Inc.
Phase 2Completed8Jun 23, 2023Registry ↗
Feb 11, 2026A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
NCT07402876 · Primary Vitreoretinal Lymphoma
ICM ADX-2191 injection, Monthly ADX-2191 injection
ALDX
Aldeyra Therapeutics, Inc.
Phase 3Recruiting20Dec 2026Registry ↗
Dec 22, 2025A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
NCT06493604 · Dry Eye Disease
Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic…
ALDX
Aldeyra Therapeutics, Inc.
Phase 3Completed116Feb 27, 2025Registry ↗
Nov 26, 2025A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evalua…
NCT04735393 · Dry Eye Disease
Reproxalap Ophthalmic Solution (0.25%), Placebo Comparator
ALDX
Aldeyra Therapeutics, Inc.
Phase 3Completed757Oct 11, 2022Registry ↗
Oct 1, 2025A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
NCT06424444 · Dry Eye Disease
Reproxalap ophthalmic solution (0.25%), Vehicle ophthalmic…
ALDX
Aldeyra Therapeutics, Inc.
Phase 3Completed421Nov 3, 2024Registry ↗
Jul 9, 2025The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
NCT04136366 · Proliferative Vitreoretinopathy
ADX-2191 (intravitreal methotrexate 0.8%), Standard surgica…
ALDX
Aldeyra Therapeutics, Inc.
Phase 3Completed106Jun 14, 2022Registry ↗
Jun 5, 2025A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease
NCT06389214 · Dry Eye Disease
Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic…
ALDX
Aldeyra Therapeutics, Inc.
Phase 3Completed132Jun 11, 2024Registry ↗
Apr 8, 2025A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Alle…
NCT03660878 · Allergic Conjunctivitis
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalm…
ALDX
Aldeyra Therapeutics, Inc.
Phase 1/2Completed52Nov 19, 2019Registry ↗
Mar 19, 2025The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Di…
NCT04674358 · Dry Eye, Dry Eye Syndromes
Reproxalap Ophthalmic Solution (0.25%), Vehicle Opthalmic S…
ALDX
Aldeyra Therapeutics, Inc.
Phase 2/3Completed329Sep 12, 2021Registry ↗
Mar 18, 2025The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects Wit…
NCT05062330 · Dry Eye
Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic…
ALDX
Aldeyra Therapeutics, Inc.
Phase 3Completed361Mar 4, 2022Registry ↗
Mar 11, 2025A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psorias…
NCT04908514 · Plaque Psoriasis
ADX-629
ALDX
Aldeyra Therapeutics, Inc.
Phase 2Completed10Jan 21, 2022Registry ↗
Mar 3, 2025A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Re…
NCT03916042 · Dry Eye
Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QI…
ALDX
Aldeyra Therapeutics, Inc.
Phase 2Completed206Nov 22, 2019Registry ↗
Feb 28, 2025A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethano…
NCT05487404 · Ethanol Intoxication
ADX-629, Placebo
ALDX
Aldeyra Therapeutics, Inc.
Phase 1/2Completed26May 29, 2022Registry ↗
Feb 28, 2025A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough
NCT05392192 · Chronic Cough
ADX-629, Placebo
ALDX
Aldeyra Therapeutics, Inc.
Phase 2Completed51Apr 13, 2023Registry ↗
Feb 28, 2025An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a…
NCT05102409 · Dry Eye
Reproxalap Ophthalmic Solution (0.25%), Xiidra® (5% lifiteg…
ALDX
Aldeyra Therapeutics, Inc.
Phase 2Completed56Oct 25, 2021Registry ↗
Feb 24, 2025A Clinical Trial to Assess Subjects With Dry Eye Disease.
NCT04971031 · Dry Eye
Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic…
ALDX
Aldeyra Therapeutics, Inc.
Phase 2Completed158Sep 8, 2021Registry ↗
Feb 24, 2025A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjuncti…
NCT03709121 · Conjunctivitis, Allergic
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalm…
ALDX
Aldeyra Therapeutics, Inc.
Phase 1/2Completed70Mar 20, 2019Registry ↗
Feb 17, 2025A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability…
NCT04847544 · Covid19
ADX-629, Placebo
ALDX
Aldeyra Therapeutics, Inc.
Phase 2Completed11Oct 15, 2021Registry ↗
Feb 17, 2025A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety…
NCT04728711 · Atopic Asthma
ADX-629, Placebo
ALDX
Aldeyra Therapeutics, Inc.
Phase 2Completed8Jan 18, 2022Registry ↗
Feb 11, 2025ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
NCT03494504 · Allergic Conjunctivitis
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalm…
ALDX
Aldeyra Therapeutics, Inc.
Phase 3Completed318Nov 5, 2018Registry ↗
Feb 10, 2025SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.
NCT03131154 · Non-infectious Anterior Uveitis
ADX-102 Ophthalmic Solution (0.5%), Vehicle of ADX-102 Opht…
ALDX
Aldeyra Therapeutics, Inc.
Phase 3Completed123Apr 19, 2019Registry ↗
Feb 6, 2025A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to As…
NCT03404115 · Dry Eye Syndrome
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalm…
ALDX
Aldeyra Therapeutics, Inc.
Phase 2Completed300Jul 11, 2018Registry ↗
Jan 23, 2025The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Ada…
NCT03879863 · Dry Eye
Reproxalap Ophthalmic Solution (0.25%) QID, Vehicle Ophthal…
ALDX
Aldeyra Therapeutics, Inc.
Phase 3Completed422Oct 4, 2019Registry ↗
Jan 16, 2025A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
NCT03162783 · Dry Eye Syndromes
ADX-102 Ophthalmic Solution (0.5%), ADX-102 Ophthalmic Solu…
ALDX
Aldeyra Therapeutics, Inc.
Phase 2Completed51Jul 6, 2017Registry ↗
Jan 15, 2025A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease
NCT05424549 · Dry Eye Syndromes
Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic…
ALDX
Aldeyra Therapeutics, Inc.
Phase 2Completed63May 9, 2022Registry ↗
Nov 20, 2024The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal…
NCT04207736 · Allergic Conjunctivitis
Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic…
ALDX
Aldeyra Therapeutics, Inc.
Phase 3Completed95Feb 16, 2021Registry ↗
Apr 17, 2024Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syn…
NCT05599815 · Nephrotic Syndrome
ADX-629
ALDX
Aldeyra Therapeutics, Inc.
Phase 2Withdrawn0May 2023Registry ↗
Dec 5, 2023A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis
NCT02578914 · Allergic Conjunctivitis, Seasonal Allergies
NS2 Ophthalmic Drops (0.5%), NS2 Ophthalmic Drops Vehicle (…
ALDX
Aldeyra Therapeutics, Inc.
Phase 2Completed100Dec 2015Registry ↗
Mar 27, 2023A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis
NCT02406209 · Non-infectious Anterior Uveitis
NS2, Prednisolone acetate ophthalmic suspension (1%)
ALDX
Aldeyra Therapeutics, Inc.
Phase 2Completed45Apr 2016Registry ↗
Feb 9, 2023RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)
NCT03445650 · Sjogren-Larsson Syndrome
ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of AD…
ALDX
Aldeyra Therapeutics, Inc.
Phase 3Completed11Jan 18, 2020Registry ↗
Jan 9, 2023A Study of ADX-102 in Subjects With Allergic Conjunctivitis
NCT03012165 · Conjunctivitis, Allergic
ADX-102 Ophthalmic Drops (0.5%), ADX-102 Ophthalmic Drops (…
ALDX
Aldeyra Therapeutics, Inc.
Phase 2Completed154May 2017Registry ↗
Dec 13, 2022A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
NCT02402309 · Sjögren-Larsson Syndrome
Active topical NS2 1% dermatologic cream, Vehicle placebo 0…
ALDX
Aldeyra Therapeutics, Inc.
Phase 2Completed12May 2016Registry ↗

35 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:37 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances